In:
American Journal of Hospice and Palliative Medicine®, SAGE Publications, Vol. 33, No. 5 ( 2016-06), p. 456-462
Abstract:
To compare the efficacy of antipsychotics (APs) for delirium treatment in patients with cancer, 27 patients treated with 1 of the 4 APs, haloperidol (HPD), risperidone (RIS), olanzapine (OLZ), and quetiapine (QTP), were divided into 2 groups: long half-life (T1/2; HPD, RIS, and OLZ) versus short T1/2 (QTP) or the multiacting receptor-targeted APs (MARTAs; OLZ and QTP) versus the non-MARTA (HPD and RIS). The symptom severity was evaluated by the memorial delirium rating scale (MDAS) on days 0, 3, and 7 following intervention. Significant improvements in total MDAS scores were found in all groups on day 3. However, on day 7, only the short T1/2 group and MARTA group showed significant improvement. Consideration of an AP’s pharmacological properties may be helpful for improving the outcomes of pharmacological delirium intervention in patients with cancer.
Type of Medium:
Online Resource
ISSN:
1049-9091
,
1938-2715
DOI:
10.1177/1049909114565019
Language:
English
Publisher:
SAGE Publications
Publication Date:
2016
detail.hit.zdb_id:
2236674-X
Bookmarklink